The paper's citation list
No. | The paper's citation list |
|---|
1 | Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease. 2022;13:53 doi: 10.3390/biom13010053 |
2 | Cation-independent mannose 6-phosphate receptor: From roles and functions to targeted therapies. 2024;365:759 doi: 10.1016/j.jconrel.2023.12.014 |
3 | Recent Therapeutic Advancements for Gaucher Disease. 2025;8: doi: 10.1002/adtp.202400292 |
4 | Best Practices for Development and Validation of Enzymatic Activity Assays to Support Drug Development for Inborn Errors of Metabolism and Biomarker Assessment. 2024;26: doi: 10.1208/s12248-024-00966-y |
5 | Exploring the potential of bacterial-derived EVs for targeted enzyme replacement therapy: mechanisms, applications, and future directions. 2025;207: doi: 10.1007/s00203-025-04294-3 |
6 | Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. 2022;23:14340 doi: 10.3390/ijms232214340 |
7 | Investigation on Cross-correction of Cystinosis through Genetically
Engineered Cells Secreting Cystinosin. 2024;13:46 doi: 10.2174/0122115501271925231130074832 |
8 | Clinical Applications of Biomolecules in Disease Diagnosis. 2024;233 doi: 10.1007/978-981-97-4723-8_10 |
9 | Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease. 2024;10: doi: 10.1126/sciadv.adq4738 |
10 | From Molecular Therapies to Lysosomal Transplantation and Targeted Drug Strategies: Present Applications, Limitations, and Future Prospects of Lysosomal Medications. 2025;15:327 doi: 10.3390/biom15030327 |
11 | Extracellular Vesicles as Tools for Crossing the Blood–Brain Barrier to Treat Lysosomal Storage Diseases. 2025;15:70 doi: 10.3390/life15010070 |
